{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:14:21Z","timestamp":1769728461019,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.amjms.2022.07.007","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T02:09:36Z","timestamp":1660270176000},"page":"93-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab"],"prefix":"10.1016","volume":"365","author":[{"given":"Georgios","family":"Tsioulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitris","family":"Kounatidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia G.","family":"Vallianou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nektarios","family":"Koufopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pelagia","family":"Katsimbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Antoniadou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjms.2022.07.007_bib0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/08916930400022673","article-title":"Antineutrophil cytoplasmic antibodies (ANCA)","volume":"38","author":"Radice","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.amjms.2022.07.007_bib0002","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-019-12515-9","article-title":"European Vasculitis Genetics Consortium. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratifed by ANCA status","volume":"10","author":"Lyons","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.amjms.2022.07.007_bib0003","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MD.0b013e3181af35a5","article-title":"Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis","volume":"88","author":"Neumann","year":"2009","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.amjms.2022.07.007_bib0004","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/art.41062","article-title":"A neutrophil activation biomarker panel in prognosis and monitoring of patients with rheumatoid arthritis","volume":"72","author":"Bach","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.amjms.2022.07.007_bib0005","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3899\/jrheum.190875","article-title":"Role of Neutrophil extracellular traps regarding patients at risk of increased disease activity and cardiovascular comorbidity in systemic lupus erythematosus","volume":"47","author":"Moore","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjms.2022.07.007_bib0006","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10753-007-9032-4","article-title":"Eosinophil cationic protein stimulates TGF-\u03b21 release by human lung fibroblasts in vitro","volume":"30","author":"Zagai","year":"2007","journal-title":"Inflammation"},{"key":"10.1016\/j.amjms.2022.07.007_bib0007","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2020.12.008","article-title":"Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): prospective evaluation at a tertiary referral centre","volume":"85","author":"Zampieri","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.amjms.2022.07.007_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.627776","article-title":"Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology","volume":"8","author":"Fagni","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.amjms.2022.07.007_bib0009","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.autrev.2017.07.007","article-title":"Central nervous system involvement in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): report of 26 patients and review of the literature","volume":"16","author":"Andre","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.amjms.2022.07.007_bib0010","doi-asserted-by":"crossref","DOI":"10.1007\/s00296-021-04950-z","article-title":"Multitargeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a casebased review","author":"Mutoh","year":"2021","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.amjms.2022.07.007_bib0011","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3109\/14397595.2014.940126","article-title":"Rapid onset of small intestinal perforation after successful steroid treatment in eosinophilic granulomatosis with polyangiitis","volume":"26","author":"Ikeda","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.amjms.2022.07.007_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.carpath.2019.107193","article-title":"Multiple ulcerations and\u2002perforation\u2002in the small intestine after steroid treatment in eosinophilic granulomatosis with polyangiitis: a case report and literature review","volume":"47","author":"Ito","year":"2020","journal-title":"Cardiovasc Pathol"},{"issue":"5","key":"10.1016\/j.amjms.2022.07.007_bib0013","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2169\/internalmedicine.8975-17","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss Syndrome) complicated by\u2002perforation\u2002of the small intestine and cholecystitis","volume":"57","author":"Ohnuki","year":"2018","journal-title":"Intern Med"},{"issue":"2","key":"10.1016\/j.amjms.2022.07.007_bib0014","doi-asserted-by":"crossref","first-page":"67","DOI":"10.12998\/wjcc.v5.i2.67","article-title":"Multiple perforations and fistula formation following corticosteroid administration: a case report","volume":"5","author":"He","year":"2017","journal-title":"World J Clin Cases"},{"issue":"1","key":"10.1016\/j.amjms.2022.07.007_bib0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"French Vasculitis Study Group (FVSG). The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.amjms.2022.07.007_bib0016","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjms.2022.07.007_bib0017","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/art.23198","article-title":"Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients","volume":"58","author":"Ribi","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjms.2022.07.007_bib0018","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.rdc.2010.05.003","article-title":"Clinical manifestations and treatment of Churg-Strauss syndrome","volume":"36","author":"Baldini","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.amjms.2022.07.007_bib0019","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2013.03.003","article-title":"Long-term outcomes of 118 patientswith eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials","volume":"43","author":"Samson","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.amjms.2022.07.007_bib0020","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjms.2022.07.007_bib0021","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.amjms.2022.07.007_bib0022","first-page":"171","article-title":"Canadian Vasculitis Network (CanVasc). Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-center cohort","volume":"38","author":"Doubelt","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.amjms.2022.07.007_bib0023","doi-asserted-by":"crossref","DOI":"10.1186\/ar4313","article-title":"Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)","volume":"15","author":"Thiel","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.amjms.2022.07.007_bib0024","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjms.2022.07.007_bib0025","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2147\/TCRM.S159949","article-title":"Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy","volume":"14","author":"Faverio","year":"2018","journal-title":"Ther Clin Risk Manag"},{"issue":"20","key":"10.1016\/j.amjms.2022.07.007_bib0026","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"EGPA mepolizumab study team. Mepolizumab\u2002or placebo for eosinophilic granulomatosis with polyangiitis","volume":"18","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2022.07.007_bib0027","first-page":"112","article-title":"Refractory diffuse alveolar hemorrhage caused by eosinophilic granulomatosis with polyangiitis in the absence of elevated biomarkers treated successfully by rituximab and mepolizumab: a case report","volume":"26","author":"Shiroshita","year":"2019","journal-title":"Respir Med Case Rep"},{"issue":"7","key":"10.1016\/j.amjms.2022.07.007_bib0028","first-page":"e9242","article-title":"Concurrent use of mepolizumab and rituximab for eosinophilic granulomatosis with polyangiitis and multisystem involvement","volume":"12","author":"Afiari","year":"2020","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.amjms.2022.07.007_bib0029","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11926-018-0736-2","article-title":"Eosinophilic granulomatosis with polyangiitis: newer therapies","volume":"20","author":"Navarro-Mendoza","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.amjms.2022.07.007_bib0030","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez063.002","article-title":"Use of rituximab and mepolizumab for EGPA","volume":"58","author":"Albert","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.amjms.2022.07.007_bib0031","first-page":"1","article-title":"Rituximab and mepolizumab combination therapy for glucocorticoid-resistant myocarditis related to eosinophilic granulomatosis with polyangiitis","author":"Higashitani","year":"2021","journal-title":"Mod Rheumatol Case Rep"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962922003317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962922003317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:42:10Z","timestamp":1757702530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962922003317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0002962922003317"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2022.07.007","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2022.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}